Thereafter, a phase II study (SG035–0003 study) involving patients with recurrent or refractory CD30-positive HL after autologous hematopoietic stem cell transplantation was conducted from February 2009 [9], and another phase II study involving patients with recurrent or refractory CD30-positive systemic ALCL (sALCL) (excluding those with primary dermal ALCL localized in the skin)(SG035–0004 study) was performed from June 2009 [10]. Here, TNFRSF8 is linked to Hodgkins lymphoma.